Burden of illness: Direct and indirect costs among persons with hemophilia A in the United States

Journal of Medical Economics

Volumn 18, Issue 6, 2015, Pages 457-465

  Zhou, Zheng Yi ^a   Koerper, Marion A ^b   Johnson, Kathleen A ^a   Riske, Brenda ^c   Baker, Judith R ^a,d   Ullman, Megan ^e   Curtis, Randall G ^f   Poon, Jiat Ling ^a   Lou, Mimi ^a   Nichol, Michael B ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Center for Inherited Blood Disorders   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f Factor VIII Computing   (United States)

Author keywords

Burden of illness; Economic; Hemophilia A; Indirect cost

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8;

ABSENTEEISM; ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHILD; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; UNITED STATES; CAREGIVER; DIAGNOSTIC PROCEDURE; ECONOMICS; EPIDEMIOLOGY; HEALTH SERVICE; MEDICAL LEAVE; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UTILIZATION; YOUNG ADULT;

ABSENTEEISM; ADOLESCENT; ADULT; CAREGIVERS; CHILD; COST OF ILLNESS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; FACTOR VIII; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; MODELS, ECONOMETRIC; SEVERITY OF ILLNESS INDEX; SICK LEAVE; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84935843050     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1016228     Document Type: Article

References (33)

1. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998;59:288-94
2. Arun B, Kessler C. Inherited bleeding disorders: haemostasis and thrombosis. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkens, 2001
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44
4. Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002;8:44-50
5. Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011;9:700-10
6. National Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF. aspx?menuid57&contentid1007. Accessed April 1, 2013
7. Globe DR, Curtis RG, Koerper MA, et al. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004;10(1 Suppl):63-70
8. Carlsson KS, Hojgard S, Lindgren A, et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia 2004;10:515-26
9. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011;72:553-62
10. Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102:2358-63
11. Auerswald G, von Depka Prondzinski M, Ehlken B, et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004;10:499-508
12. Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood transfusionTrasfusione del sangue 2014;12(Suppl 3):s567-75
13. Guh S, Grosse SD, McAlister S, et al. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia 2012;18:268-75
14. Tencer T, Friedman HS, Li-McLeod J, et al. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. J Manag Care Pharm 2007;13:790-8
15. Guh S, Grosse SD, McAlister S, et al. Health care expenditures for Medicaidcovered males with haemophilia in the United States, 2008. Haemophilia 2012;18:276-83
16. Valentino LA, Pipe SW, Tarantino MD, et al. Healthcare resource utilization among haemophilia A patients in the United States. Haemophilia 2012;18:332-8
17. Zhou ZY, Wu J, Baker J, et al. Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data. Haemophilia 2011;17: 729-36
18. Baker JR, Crudder SO, Riske B, et al. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health 2005;95:1910-16
19. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000;96:437-42
20. Soucie JM, Symons JT, Evatt B, et al. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001;7:198-206
21. Drake JH, Soucie JM, Cutter SC, et al. High school completion rates among men with hemophilia. Am J Prev Med 2010;38(4 Suppl):S489-94
22. HCUPnet: a tool for identifying, tracking, and analyzing national hospital statistics. http://hcupnet.ahrq.gov/HCUPnet.jsp. Accessed May 2, 2012
23. Centers for Medicare & Medicaid Services. MEDPAR. http://www.cms. gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareFeeforSvcPartsAB/MEDPAR.html. Accessed April 28, 2012
24. Machlin S, Chowdhury S. Expenses and characteristics of physician visits in different ambulatory care settings, 2008. http://meps.ahrq.gov/mepsweb/data-files/publications/st318/stat318.pdf. Accessed April 24, 2012
25. Centers for Medicare & Medicaid Services. Medicare Physician Fee Schedule. http://www.cms.gov/apps/physician-fee-schedule/. Accessed April 22, 2012
26. Centers for Medicare & Medicaid Services. Medicare Part B Drug Average Sales Price. https://www.cms.gov/Medicare/Medicare-Fee-for- Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html. Accessed April 26, 2012
27. Ready price. 2012. http://www.micromedexsolutions.com/home/dispatch. Accessed January 27, 2012
28. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982;60: 429-62
29. U.S. Bureau of Labor Statistics. Employer costs per hour worked for employee compensation. 2011. www.bls.gov/. Accessed February 24, 2012
30. Agency for Healthcare Research and Quality. Total health services-mean and median expenses per person with expense and distribution of expenses by source of payment: United States, 2010. Medical Expenditure Panel Survey Household Component Data. http://meps.ahrq.gov/survey-comp/household.jsp. Accessed April 28, 2013
31. Centers For Disease Control and Prevention Blood Disorders. Information for hemophilia treatment centers. http://www.cdc.gov/ncbddd/blooddisorders/udc/udc-hemophilia.html. Accessed April 10, 2013
32. Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004;103:2467-73
33. Baker JR, Riske B, Drake JH, et al. US Hemophilia Treatment Center population trends 1990-2010: patient diagnoses, demographics, health services utilization. Haemophilia 2013;19:21-6